HELP
Cybin D/B/A Helus Pharma
Price Chart
Latest Quote
$10.66
+0.30 (+2.90%)
Current Price
| Previous Close | $10.36 |
| Open | $10.44 |
| Day High | $10.68 |
| Day Low | $9.71 |
| Volume | 1,121,681 |
Stock Information
| Shares Outstanding | 73.06M |
| Cash Equivalents | $166.36M |
| Net Income | $-171.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $778.82M |
| EPS (TTM) | $-4.15 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $590.54M |
| Income | $-171.20M |
| Book/sh | $3.91 |
| Cash/sh | $2.28 |
| Employees | 100 |
Financial Ratios
| Quick Ratio | 9.76 |
| Current Ratio | 10.97 |
Returns & Margins
| ROA | -44.38% |
| ROE | -86.94% |
Ownership
| Insider Ownership | 12.88% |
| Institutional Ownership | 41.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.06 |
| P/B | 2.73 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $41.25 |
Technical Indicators
| SMA20 | $10.94 |
| SMA50 | $12.04 |
| SMA200 | $7.67 |
| RSI | 51.37 |
| ATR | 0.9720 |
| Shares Float | 58.10M |
| Short Ratio | 2.02 |
| Volatility | 0.54 |
| Rel Volume | 0.76 |
Performance History
| Week | -2.56% |
| Month | -15.33% |
| Quarter | +34.77% |
| 6 Months | +106.59% |
| YTD | +28.74% |
| Year | +72.77% |
| 3 Years | -42.16% |
| 5 Years | -85.39% |
| 10 Years | -78.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $10.66 | 1,121,681 |
| 2026-10-26 | $10.36 | 1,033,300 |
| 2026-10-23 | $10.19 | 1,892,800 |
| 2026-10-22 | $10.50 | 1,915,500 |
| 2026-10-21 | $10.78 | 933,200 |
| 2026-10-20 | $10.94 | 2,362,600 |
| 2026-10-19 | $10.69 | 975,300 |
| 2026-10-16 | $10.55 | 1,311,400 |
| 2026-10-15 | $11.05 | 1,534,000 |
| 2026-10-14 | $10.38 | 1,051,800 |
| 2026-10-13 | $10.50 | 3,173,700 |
| 2026-10-12 | $11.03 | 2,336,600 |
| 2026-10-09 | $11.80 | 1,659,300 |
| 2026-10-08 | $10.72 | 1,116,400 |
| 2026-10-07 | $10.51 | 832,100 |
| 2026-10-06 | $10.76 | 1,476,600 |
| 2026-10-05 | $11.42 | 1,319,300 |
| 2026-10-02 | $11.70 | 1,405,400 |
| 2026-10-01 | $11.91 | 1,327,500 |
| 2026-09-30 | $12.29 | 822,700 |
| 2026-09-29 | $12.70 | 967,300 |
| 2026-09-28 | $12.59 | 985,900 |
About Cybin D/B/A Helus Pharma
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
đ° Latest News
No news articles available at the moment. Check back later for updates on HELP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | - |
| Cost Of Revenue | - | - | - | - |
| Expenses | ||||
| Total Expenses | $142,587,000 | $103,125,000 | $78,836,000 | $51,518,000 |
| Other Income Expense | $-7,594,000 | $15,548,000 | $137,000 | $3,425,000 |
| Other Non Operating Income Expenses | $-2,586,000 | - | - | - |
| Net Non Operating Interest Income Expense | $2,183,000 | $5,990,000 | $619,000 | $603,000 |
| Total Other Finance Cost | $2,917,000 | - | - | - |
| Operating Expense | $142,587,000 | $103,125,000 | $78,836,000 | $51,518,000 |
| Selling And Marketing Expense | $6,448,000 | $2,353,000 | $2,805,654 | $881,000 |
| General And Administrative Expense | $49,551,000 | $61,561,000 | $31,588,958 | $25,146,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Net Interest Income | $2,183,000 | $5,990,000 | $619,000 | $603,000 |
| Interest Income | $5,100,000 | $5,990,000 | $619,000 | $603,000 |
| Normalized Income | $-142,990,000 | $-97,155,000 | $-78,217,000 | $-50,915,000 |
| Net Income From Continuing And Discontinued Operation | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Net Income Common Stockholders | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Net Income | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Net Income Including Noncontrolling Interests | $-147,998,000 | $-81,587,000 | $-78,080,000 | $-47,490,000 |
| Net Income Continuous Operations | $-147,998,000 | $-81,587,000 | $-78,080,000 | $-47,490,000 |
| Pretax Income | $-147,998,000 | $-81,587,000 | $-78,080,000 | $-47,490,000 |
| Interest Income Non Operating | $5,100,000 | $5,990,000 | $619,000 | $603,000 |
| Operating Income | $-142,587,000 | $-103,125,000 | $-78,836,000 | $-51,518,000 |
| Special Income Charges | - | $-28,000 | $0 | $-342,000 |
| Gross Profit | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-4.25 | $-4.04 | $-6.96 | $-9.88 |
| Basic EPS | $-4.25 | $-4.04 | $-6.96 | $-9.88 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-137,459,000 | $-118,325,000 | $-78,549,000 | $-54,692,000 |
| Total Unusual Items | $-5,008,000 | $15,548,000 | $137,000 | $3,425,000 |
| Total Unusual Items Excluding Goodwill | $-5,008,000 | $15,548,000 | $137,000 | $3,425,000 |
| Reconciled Depreciation | $120,000 | $348,000 | $424,000 | $251,000 |
| EBITDA (Bullshit earnings) | $-142,467,000 | $-102,777,000 | $-78,412,000 | $-51,267,000 |
| EBIT | $-142,587,000 | $-103,125,000 | $-78,836,000 | $-51,518,000 |
| Diluted Average Shares | $34,802,943 | $20,222,493 | $8,297,370 | $4,879,704 |
| Basic Average Shares | $34,802,943 | $20,222,493 | $8,297,370 | $4,879,704 |
| Diluted NI Availto Com Stockholders | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Gain On Sale Of Security | $-5,008,000 | $15,548,000 | $137,000 | $3,767,000 |
| Research And Development | $86,588,000 | $39,211,000 | $32,362,000 | $25,491,000 |
| Selling General And Administration | $55,999,000 | $63,914,000 | $46,474,000 | $26,027,000 |
| Other Gand A | $28,723,000 | $20,857,000 | $15,207,963 | $14,188,000 |
| Salaries And Wages | $20,828,000 | $40,704,000 | $22,134,000 | $10,958,000 |
| Other Special Charges | - | $28,000 | - | - |
| Restructuring And Mergern Acquisition | - | - | $0 | $342,000 |
| Write Off | - | - | - | - |
| Impairment Of Capital Assets | - | - | - | - |
Fetched: 2026-10-07
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $165,340,000 | $100,650,000 | $208,987,000 | $17,972,000 |
| Total Assets | $251,166,000 | $179,897,000 | $302,023,000 | $53,897,000 |
| Total Non Current Assets | $66,644,000 | $64,445,000 | $83,487,000 | $30,712,000 |
| Goodwill And Other Intangible Assets | $66,449,000 | $64,347,000 | $82,940,000 | $30,262,000 |
| Other Intangible Assets | $30,224,000 | $28,532,000 | $35,465,000 | $5,470,000 |
| Current Assets | $184,522,000 | $115,452,000 | $218,536,000 | $23,185,000 |
| Prepaid Assets | $22,236,000 | $15,412,000 | $2,891,000 | $1,733,000 |
| Receivables | $5,028,000 | $4,094,000 | $4,476,000 | $3,050,000 |
| Accounts Receivable | $5,028,000 | $4,094,000 | $4,476,000 | $3,050,000 |
| Cash Cash Equivalents And Short Term Investments | $157,258,000 | $93,922,000 | $208,992,000 | $16,633,000 |
| Cash And Cash Equivalents | $157,258,000 | $93,922,000 | $208,992,000 | $16,633,000 |
| Cash Financial | $157,258,000 | $93,922,000 | $208,992,000 | $16,633,000 |
| Other Current Assets | - | $2,024,000 | $2,177,000 | $1,769,000 |
| Debt | ||||
| Total Debt | - | $0 | $291,000 | - |
| Current Debt And Capital Lease Obligation | - | - | $291,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,377,000 | $14,900,000 | $10,096,000 | $5,663,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $19,377,000 | $14,900,000 | $10,096,000 | $5,663,000 |
| Payables And Accrued Expenses | $19,377,000 | $14,900,000 | $7,256,513 | $5,663,000 |
| Payables | - | $21,418,000 | $7,256,513 | $5,663,000 |
| Accounts Payable | - | $21,418,000 | $9,805,000 | $5,663,000 |
| Other Payable | - | - | $291,000 | - |
| Tradeand Other Payables Non Current | - | - | - | - |
| Other Non Current Liabilities | - | - | - | - |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $231,789,000 | $164,997,000 | $291,927,000 | $48,234,000 |
| Total Equity Gross Minority Interest | $231,789,000 | $164,997,000 | $291,927,000 | $48,234,000 |
| Stockholders Equity | $231,789,000 | $164,997,000 | $291,927,000 | $48,234,000 |
| Other Equity Interest | $86,167,000 | $56,755,000 | $64,816,000 | $38,156,000 |
| Gains Losses Not Affecting Retained Earnings | $8,083,000 | $-14,296,000 | $-2,285,000 | $-2,035,000 |
| Other Equity Adjustments | $8,083,000 | $-14,296,000 | $-2,285,000 | $-2,035,000 |
| Retained Earnings | $-389,535,000 | $-255,393,000 | $-226,231,000 | $-148,151,000 |
| Other | ||||
| Ordinary Shares Number | $51,631,804 | $21,610,704 | $20,002,353 | $5,154,191 |
| Share Issued | $51,631,804 | $21,610,704 | $20,002,353 | $5,154,191 |
| Tangible Book Value | $165,340,000 | $100,650,000 | $208,987,000 | $17,972,000 |
| Invested Capital | $231,789,000 | $164,997,000 | $291,927,000 | $48,234,000 |
| Working Capital | $165,145,000 | $100,552,000 | $208,440,000 | $17,522,000 |
| Total Capitalization | $231,789,000 | $164,997,000 | $291,927,000 | $48,234,000 |
| Additional Paid In Capital | $34,972,000 | $32,626,000 | $11,750,000 | $2,102,000 |
| Capital Stock | $492,102,000 | $345,305,000 | $443,877,000 | $158,162,000 |
| Common Stock | $492,102,000 | $345,305,000 | $443,877,000 | $158,162,000 |
| Goodwill | $36,225,000 | $35,815,000 | $47,475,000 | $24,792,000 |
| Net PPE | $195,000 | $98,000 | $547,000 | $450,000 |
| Accumulated Depreciation | $-616,000 | $-589,000 | $-807,000 | $-453,000 |
| Gross PPE | $811,000 | $687,000 | $1,354,000 | $903,000 |
| Other Properties | $413,000 | $477,000 | $1,088,000 | $664,000 |
| Machinery Furniture Equipment | $398,000 | $210,000 | $266,000 | $239,000 |
| Capital Lease Obligations | - | $0 | $291,000 | - |
| Current Capital Lease Obligation | - | $0 | $291,000 | - |
| Treasury Shares Number | - | - | $0 | - |
| Investments And Advances | - | - | - | $0 |
Fetched: 2026-10-07
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-134,644,000 | $-73,724,000 | $-69,618,000 | $-50,740,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-133,271,000 | $-72,328,000 | $-68,908,000 | $-47,431,000 |
| Cash Flow From Continuing Operating Activities | $-133,271,000 | $-72,328,000 | $-68,908,000 | $-47,431,000 |
| Operating Gains Losses | $-499,000 | $-15,548,000 | $-137,000 | $-4,025,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,373,000 | $-1,396,000 | $-710,000 | $-3,309,000 |
| Investing Cash Flow | $-1,363,000 | $-1,396,000 | $6,922,000 | $-3,309,000 |
| Cash Flow From Continuing Investing Activities | $-1,363,000 | $-1,396,000 | $6,922,000 | $-3,309,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $146,052,000 | $14,305,000 | $254,600,000 | $13,202,000 |
| Financing Cash Flow | $198,239,000 | $14,095,000 | $254,507,000 | $13,564,000 |
| Cash Flow From Continuing Financing Activities | $198,239,000 | $14,095,000 | $254,507,000 | $13,564,000 |
| Net Other Financing Charges | $-315,000 | - | - | - |
| Net Common Stock Issuance | $146,052,000 | $14,305,000 | $254,600,000 | $13,202,000 |
| Common Stock Issuance | $146,052,000 | $14,305,000 | $254,600,000 | $13,202,000 |
| Other | ||||
| Repayment Of Debt | $-20,150,000 | $-210,000 | $-149,000 | $0 |
| Issuance Of Debt | $44,500,000 | $0 | - | - |
| Interest Paid Supplemental Data | $-5,500,000 | $0 | - | - |
| Income Tax Paid Supplemental Data | $0 | $0 | - | - |
| End Cash Position | $157,258,000 | $93,922,000 | $208,992,000 | $16,633,000 |
| Beginning Cash Position | $93,922,000 | $154,238,000 | $16,633,000 | $53,641,000 |
| Effect Of Exchange Rate Changes | $-269,000 | $-687,000 | $-162,000 | $168,000 |
| Changes In Cash | $63,605,000 | $-59,629,000 | $192,521,000 | $-37,176,000 |
| Proceeds From Stock Option Exercised | $28,152,000 | $0 | $56,000 | $362,000 |
| Net Issuance Payments Of Debt | $24,350,000 | $-210,000 | $-149,000 | $0 |
| Net Short Term Debt Issuance | $24,350,000 | $0 | - | - |
| Short Term Debt Payments | $-20,150,000 | $0 | - | - |
| Short Term Debt Issuance | $44,500,000 | $0 | - | - |
| Net Long Term Debt Issuance | $0 | $-210,000 | $-149,000 | $0 |
| Long Term Debt Payments | $0 | $-210,000 | $-149,000 | $0 |
| Net PPE Purchase And Sale | $-1,363,000 | $-1,396,000 | $-525,459 | $-142,000 |
| Sale Of PPE | $10,000 | $0 | - | - |
| Purchase Of PPE | $-1,373,000 | $-1,396,000 | $-525,459 | $-142,000 |
| Change In Working Capital | $-1,257,000 | $-6,823,000 | $-5,027,000 | $-1,437,000 |
| Change In Other Current Assets | $2,024,000 | $-417,000 | $-408,000 | $-428,000 |
| Change In Payables And Accrued Expense | $4,477,000 | $7,662,000 | $-2,544,000 | $401,000 |
| Change In Prepaid Assets | $-6,824,000 | $-13,278,000 | $-986,000 | $-462,000 |
| Change In Receivables | $-934,000 | $-790,000 | $-1,089,000 | $-948,000 |
| Changes In Account Receivables | $-934,000 | $-790,000 | $-1,089,000 | $-948,000 |
| Stock Based Compensation | $10,863,000 | $31,282,000 | $13,886,000 | $4,686,000 |
| Unrealized Gain Loss On Investment Securities | $5,500,000 | $0 | $0 | $260,000 |
| Depreciation Amortization Depletion | $120,000 | $348,000 | $424,000 | $251,000 |
| Depreciation And Amortization | $120,000 | $348,000 | $424,000 | $251,000 |
| Amortization Cash Flow | $32,000 | $65,000 | $61,000 | $37,000 |
| Amortization Of Intangibles | $32,000 | $65,000 | $61,000 | $37,000 |
| Depreciation | $88,000 | $410,000 | $363,000 | $214,000 |
| Net Foreign Currency Exchange Gain Loss | $-492,000 | $-15,548,000 | $-137,000 | $-4,025,000 |
| Gain Loss On Sale Of PPE | $-7,000 | $0 | - | - |
| Net Income From Continuing Operations | $-147,998,000 | $-81,607,000 | $-78,080,000 | $-47,490,000 |
| Net Business Purchase And Sale | - | $0 | $7,632,000 | $0 |
| Sale Of Business | - | $0 | $7,632,000 | $0 |
| Other Non Cash Items | - | $20,000 | $8,000 | $324,000 |
| Asset Impairment Charge | - | $0 | $18,000 | $0 |
| Net Intangibles Purchase And Sale | - | - | $-689,000 | $-3,167,000 |
| Purchase Of Intangibles | - | - | $-689,000 | $-3,167,000 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Purchase Of Investment | - | - | - | $0 |
| Purchase Of Business | - | - | - | - |
| Change In Inventory | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-10-07